Capstone Therapeutics Corp. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from continuous operations before taxes of $1,234,000 compared to $1,202,000 a year ago. The company incurred a net loss of $1.2 million compared to a net loss of $1.2 million in the third quarter of 2013. Net loss is affected by the inclusion of the operating expenses of joint venture, LipimetiX Development, LLC, which totaled (net of intercompany transactions) $790,000 for the three months ended September 30, 2014, and $840,000 for the three months ended September 30, 2013. Net loss per basic and diluted share attributable to the company stockholders was $0.03 compared to $0.03 a year ago.

For the nine months, the company reported loss from continuous operations before taxes of $3,647,000 compared to $3,420,000 a year ago. The company incurred a net loss of $3.6 million compared to a net loss of $3.2 million in 2013. Net loss in 2014 increased primarily due to less other income in 2014 and the allocation of 100% of the joint venture losses to the company in 2014. Net loss per basic and diluted share attributable to the company stockholders was $0.09 compared to $0.08 a year ago.